Stockholm – Despite the availability of an effective vaccine and improved treatment outcomes, between 2.4 and 4.1 million people in the European Union (EU) and the European Economic Area (EU/EEA) remain infected with hepatitis B. Many infections are attributed to a new estimate published in Eurosurveillance...
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
Stockholm – Despite the availability of an effective vaccine and improved treatment outcomes, between 2.4 and 4.1 million people in the European Union (EU) and the European Economic Area (EU/EEA) remain infected with hepatitis B. Many infections are attributed to a new estimate published in Eurosurveillance...